gallstones/headache

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 19 rezilta yo

[The 452th case: rash, hypotension, abdominal pain and headache].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized with multiple organ involvements. Acute acalculous cholecystitis(AAC) is an extremely rare manifestation of digestive system involvement in SLE. We reported a case of 32-year-old woman who complained skin rashes for two weeks

[Headache, fever and upper abdominal colic].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A nine year old boy who had received Ceftriaxone for one week because of suspected bacterial meningoencephalitis developed colicky abdominal pain in the right upper quadrant two days after termination of Ceftriaxone treatment. Stones in the gallbladder were identified as cause of the abdominal

Proceedings of the discussion, "Tolerability and safety of Sandostatin".

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Side effects of octreotide may be local, biochemical, gastroenterological, or endocrinological. Local pain at the injection site occurs frequently, but rarely lasts more than 15 minutes and often resolves with continued therapy and may be improved if the vial is warmed prior to injection. No

Non-steroid anti-inflammatory drugs for biliary colic.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Cholelithiasis refers to the presence of gallstones, which are concretions that form in the biliary tract, usually in the gallbladder. Cholelithiasis is one of the most common surgical problems worldwide and is particularly prevalent in most Western countries.Biliary colic is the term

Clinical results of long-term slow-release lanreotide treatment of acromegaly.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Medical therapy is frequently needed to normalize growth hormone/insulin-like growth factor I secretion in acromegaly. The aim of this study was to determine the long-term effects of the slow-release (SR) somatostatin analogue lanreotide in 57 acromegalic patients. SR lanreotide (30 mg) was given

[Effects of cholecystectomy on functional signs associated with cholelithiasis].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Two hundred hospital patients with gallstones who had been cholecystectomized on account of typical biliary colics were investigated for migraine, headache, malaise, vertigo, flatulence, diarrhoea or constipation 2, 6, 12 and 24 months after the operation. The study showed that these symptoms are

Chronic non-organic upper abdominal pain: diagnostic safety and prognosis of gastrointestinal and non-intestinal symptoms. A 5- to 7-year follow-up study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

To establish the diagnostic safety and the prognosis in outpatients with non-organic upper abdominal pain, 37 patients were followed up 5-7 years after the index investigation. In only one case had the diagnosis been changed during the follow-up period. This was in a man who erroneously had not been

GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

New depot somatostatin analogs such as lanreotide-slow release (LAN) represent a significant improvement in the medical treatment of acromegaly. Seventy-three consecutive acromegalic patients, treated by LAN, were evaluated in a retrospective monocentric study. Sixteen were excluded from further

Helicobacter pylori infection in patients with calcular cholecystitis: a hospital based study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Helicobacter pylori, a gram negative bacillus has been recognised as a public health problem and approximately half of the world population has H. pylori infection causes chronic gastritis, peptic ulcer disease and gastric malignancies. Objective of this study was to determine the

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This single-center open sequential study aimed at comparing the efficacy of a 6-month treatment with lanreotide (LAN) (60-90 mg/month i.m.), to that of octreotide (OCT) (0.3-0.6 mg/day s.c.) in 45 patients with active acromegaly (GH, 63.2+/-12.1 ng/ml, IGF-I, 757+/-67.1 ng/ml). After 6 months of OCT

Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Ten patients (seven women, three men) with active acromegaly, five previously treated and five newly diagnosed, were included in an open-label prospective trial of 3 daily subcutaneous injections of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) at increasing doses in order to

The role of Sandostatin in acromegaly.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Long-acting somatostatin analogues are extensively used for the treatment of acromegalic patients who have not been cured by surgery or for whom surgery is contraindicated or hazardous. Such an analogue, Sandostatin, has been approved for this indication in various countries and to date an overall

Prolonged therapy of chronic hepatitis C with ribavirin.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Therapy with ribavirin for 6-12 months is associated with decreases in serum aminotransferases in some patients with chronic hepatitis C. We have assessed the practicality and safety of prolonged therapy with ribavirin. Six patients with chronic hepatitis C were given 1000-1200 mg of ribavirin daily

Review of European clinical experience with fenofibrate.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Since the introduction of fenofibrate to European clinical practice in 1975, some 6.5 million patient-years of experience in the treatment of hyperlipidemia have been accumulated. A review of results of clinical trials shows fenofibrate to have a broad spectrum of lipid-lowering activity, reducing

[The adrenocortical carcinoma, a tumour of wide clinical diversity].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Over the course of a few years, an obese 52-year-old woman with a 23-year history of hypertension developed a number of abdominal complaints including gall stones. Her blood pressure became increasingly difficult to control and she developed diabetes mellitus and suffered palpitations and headaches.

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye